Jeffrey H. Cooper is a former Audit Committee Chair and Independent Director for Sierra Oncology (formerly NASDAQ:SRRA) from 2016 until 2022, until it was acquired by GlaxoSmithKline (NYSE:GSK). Mr. Cooper also previously served on the Board of Directors of Tobira Therapeutics (formerly NASDSAQ:TBRA) from 2014 until it was acquired by Allergan (now AbbVie NYSE:ABBV) in 2016. Mr. Cooper has served as an independent consultant for life sciences companies since January 2014. Previously, Mr. Cooper served at KaloBios Pharmaceuticals as a senior advisor in 2013 and as the Chief Financial Officer from 2012 until 2013.
Prior, Mr. Cooper served in positions of increasing responsibility at BioMarin Pharmaceutical (NASDSAQ:BMRN), beginning as Vice President, Controller, to his most recent position as Senior Vice President and Chief Financial Officer from 2007 to 2012. Mr. Cooper has also served as Vice President of Finance at Matrix Pharmaceutical and held numerous finance-related positions within the health care and pharmaceutical industries, including Corporate Controller at Foundation Health Systems and Director of Business Analysis at Syntex Corporation. Mr. Cooper received a B.A. from the University of California, Los Angeles and an M.B.A. from Santa Clara University.
